Drug shows potential for people with mild Alzheimer’s disease

An¬†experimental drug is showing promise in slowing the decline in thinking and memory that comes with Alzheimer’s disease, especially in people with milder forms of the illness.

Drug maker Eli Lilly & Co. announced Monday that solanezumab did not slow mental decline in each of two phase 3 clinical trials, but when the data from both studies was combined a statistically significant and positive effect was seen. This benefit seemed to be concentrated in patients with mild cases of Alzheimer’s, the company noted.

In a news release, Lilly said that combining the results of the two trials showed a 34 percent slowing of mental decline for people with mild Alzheimer’s who took solanezumab, compared to those taking a placebo.

The trial data was released Monday at an American Neurological Association conference in Boston.

“We recognize that the solanezumab studies did not meet their primary endpoints, but we are encouraged by the pooled data that appear to show a slowing of cognitive [thinking/memory] decline,” Lilly Chairman, CEO and President John Lechleiter said in a company news release.

Read the full article from Healthy Day at http://consumer.healthday.com/Article.asp?AID=669437.

Comments are closed.